NZ764072A - Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan - Google Patents
Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphanInfo
- Publication number
- NZ764072A NZ764072A NZ764072A NZ76407215A NZ764072A NZ 764072 A NZ764072 A NZ 764072A NZ 764072 A NZ764072 A NZ 764072A NZ 76407215 A NZ76407215 A NZ 76407215A NZ 764072 A NZ764072 A NZ 764072A
- Authority
- NZ
- New Zealand
- Prior art keywords
- day
- dextromethorphan
- bupropion
- twice
- orally administered
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to the use of a combination of dextromethorphan and bupropion for treating depression, by oral administration of 40-100 mg of dextromethorphan and 90-150 mg of bupropion (each in free base or salt form) once or twice a day for at least 14 days. The claimed treatment regime results in a Cmin of 3-110 ng/mL on the seventh day of administration.
Claims (10)
1. Use of a ation of dextromethorphan and bupropion for the manufacture of a medicament for treating depression, wherein the treatment comprises orally administering the ation of about 40 mg to about 100 mg of dextromethorphan in the free base or a salt form and about 90 mg to about 150 mg of bupropion in the free base or a salt form, once a day or twice a day, for at least 14 days, to a human being suffering from depression, and wherein on the seventh day, the Cmin of dextromethorphan is about 3 ng/mL to about 110 ng/mL.
2. The use of claim 1, wherein about 0.6 mg/kg to about 1 mg/kg of the dextromethorphan is to be orally administered once a day or twice a day.
3. The use of claim 1 or 2, n about 0.6 mg/kg to about 0.8 mg/kg of the dextromethorphan is to be orally administered once a day or twice a day.
4. The use of claim 1, 2, or 3, wherein about 45 mg of the dextromethorphan is to be orally administered once a day or twice a day.
5. The use of claim 1, 2, 3, or 4, wherein about 100 mg to about 150 mg of the bupropion is to be orally administered once a day or twice a day.
6. The use of claim 1, 2, 3, or 4, wherein about 95 mg to about 150 mg of the ion is to be orally administered once a day or twice a day.
7. The use of claim 1, 2, 3, or 4, wherein a total amount of about 150 mg to about 250 mg of the bupropion is to be orally administered daily.
8. The use of claim 1, 2, 3, or 4, wherein a total amount of about 105 mg to about 200 mg of the bupropion is to be orally administered daily.
9. The use of claim 1, 2, 3, or 4, wherein about 105 mg to about 150 mg of the bupropion is to be orally administered once a day or twice a day.
10. The use of claim 1, 2, 3, or 4, wherein about 100 mg to about
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/550,618 US9198905B2 (en) | 2013-11-05 | 2014-11-21 | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
| US14/555,085 US9238032B2 (en) | 2013-11-05 | 2014-11-26 | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
| US14/554,988 US9205083B2 (en) | 2013-11-05 | 2014-11-26 | Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan |
| US14/554,947 US20150126542A1 (en) | 2013-11-05 | 2014-11-26 | Compositions and Methods for Increasing the Metabolic Lifetime of Dextromethorphan and Related Pharmacodynamic Effects |
| US14/602,177 US9402843B2 (en) | 2013-11-05 | 2015-01-21 | Compositions and methods of using threohydroxybupropion for therapeutic purposes |
| US14/604,397 US9168234B2 (en) | 2013-11-05 | 2015-01-23 | Bupropion as a modulator of drug activity |
| US14/617,624 US9486450B2 (en) | 2013-11-05 | 2015-02-09 | Hydroxybupropion and related compounds as modulators of drug plasma levels |
| US14/628,062 US9402844B2 (en) | 2013-11-05 | 2015-02-20 | Methods of modulating drug plasma levels using erythrohydroxybupropion |
| NZ747111A NZ747111A (en) | 2014-11-21 | 2015-05-01 | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ764072A true NZ764072A (en) | 2022-12-23 |
Family
ID=84527790
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ764088A NZ764088A (en) | 2014-11-21 | 2015-05-01 | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
| NZ764072A NZ764072A (en) | 2014-11-21 | 2015-05-01 | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
| NZ764077A NZ764077A (en) | 2014-11-21 | 2015-05-01 | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ764088A NZ764088A (en) | 2014-11-21 | 2015-05-01 | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ764077A NZ764077A (en) | 2014-11-21 | 2015-05-01 | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Country Status (1)
| Country | Link |
|---|---|
| NZ (3) | NZ764088A (en) |
-
2015
- 2015-05-01 NZ NZ764088A patent/NZ764088A/en unknown
- 2015-05-01 NZ NZ764072A patent/NZ764072A/en unknown
- 2015-05-01 NZ NZ764077A patent/NZ764077A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ764077A (en) | 2022-12-23 |
| NZ764088A (en) | 2023-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| MX2021004639A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors. | |
| MX2017004592A (en) | Pharmaceutical formulations for the oral delivery of peptide or protein drugs. | |
| CR20210368A (en) | Combination of dextromethorphan and bupropion for treating depression | |
| MX2022003072A (en) | Use of pridopidine for treating functional decline. | |
| RS52831B (en) | Buprenorrphine wafer for drug substitution therapy | |
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| NZ628021A (en) | Pharmaceutical composition comprising empagliflozin and antiobesity drug | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| MX2022015629A (en) | Use of vibegron to treat overactive bladder. | |
| PH12019500154A1 (en) | Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof | |
| EP4282414A3 (en) | Modified release tablet formulations containing phosphodiesterase inhibitors | |
| JP2016505050A5 (en) | ||
| NZ751972A (en) | Treatment of prurigo nodularis | |
| MX2015009546A (en) | Increased dosage of efavirenz for the treatment of cancer. | |
| PH12019502510A1 (en) | Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof | |
| MX2013003523A (en) | Low dose pharmaceutical composition comprising zanamivir. | |
| MX2017005163A (en) | Onapristone extended-release compositions and methods. | |
| WO2016122288A3 (en) | Combined formulation including verbenone derivative and therapeutic agent for reperfusion for preventing or treating cerebrovascular diseases, arteriosclerosis or cardiovascular disease | |
| MY187270A (en) | Renal insufficiency progression inhibitor, prophylactic agent for renal insufficiency and indoxyl sulfate production inhibitor | |
| NZ764072A (en) | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan | |
| MX2023001014A (en) | Pharmaceutical compositions comprising venglustat. | |
| MX2022004739A (en) | Novel compound and pharmaceutical composition for prevention or treatment of cancer comprising same. | |
| EA202090416A1 (en) | METHODS FOR TREATING GASTROPARESIS SYMPTOMS USING A VELUSETRAGA | |
| MX2020006886A (en) | Drug delivery system. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAY 2024 BY ANAQUA SERVICES Effective date: 20230420 |